Hydrocotarnine|cas:550-10-7|西域试剂

Hydrocotarnine,99.59%

产品编号：Bellancom-W176629| CAS NO：550-10-7| 分子式：C₁₂H₁₅NO₃| 分子量：221.25

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-W176629	￥3200.00	杭州北京（现货）
Bellancom-W176629	￥6400.00	杭州北京（现货）
Bellancom-W176629	￥10200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Hydrocotarnine

产品介绍

Hydrocotarnine 是一种 Cbl 抑制剂，可导致结肠炎炎症小体介导的 IL-18 分泌。Hydrocotarnine 能增加细胞糖酵解代谢中的 GLUT1 表达和对葡萄糖的摄取。Hydrocotarnine 在癌症研究中具有镇痛作用。

生物活性

Hydrocotarnine is a Cbl inhibitor, and results in inflammasome-mediated IL-18 secretion in colitis. Hydrocotarnine increases expression of GLUT1 and cellular glucose uptake in glycolytic metabolism. Hydrocotarnine acts as an agent that provides analgesic effect in cancer research.

体外研究

Hydrocotarnine is an analgesic agent (CRIN-2), with the patent ID of WO2011160016A2.
Hydrocotarnine (10 μM; 1 h) elevates the secretion of IL-1β and IL-18, and (0.1-10 μM; 1 h) increases the global level of tyrosine-phosphorylated proteins in THP-1 cells.
Hydrocotarnine (50 μM; 0-100 min) increases the glycolytic capacity and glycolytic reserve capacity in THP-1-derived macrophages.
Hydrocotarnine (50 μM; 16 h) inhibits Cbl and increases the total GLUT1 protein in THP-1-derived macrophages.
Hydrocotarnine is known to enhance the analgesic effect of opioids, and alleviates cancer pain.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	THP-1 cells
Concentration:	0.1, 1, 10 μM
Incubation Time:	1 hour
Result:	Induced p-Pyk2 loss and increased the level of tyrosine-phosphorylated proteins in a dose-dependent manner.

体内研究
(In Vivo)

Hydrocotarnine (10 mg/kg/d; i.p.; 9 d) shows inhibitory effect on Cbl and results in increasing IL-18 levels, indicating that NLRP3 inflammasome activation is enhanced in mice.
Hydrocotarnine (10 mg/kg/d; i.p.; 9 d) protects mice from DSS-induced colitis, with low scores of pathological evaluation of inflammation, epithelial defects, and crypt atrophy.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DSS-induced colitis model in C57BL/6 mice (6-9 weeks old)
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; once daily; 9 days while 2.5% DSS treatment began on day 1 and ended on day 7
Result:	Significantly attenuated the weight loss of DSS-induced colitis mice compared to PBS-treated control mice, indicating that decreasing negative regulation of the NLRP3 inflammasome activation could attenuate colitis in an animal model.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DSS-induced colitis model in C57BL/6 mice (6-9 weeks old)
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; once daily; 9 days while 2.5% DSS treatment began on day 1 and ended on day 7
Result:	Significantly attenuated the weight loss of DSS-induced colitis mice compared to PBS-treated control mice, indicating that decreasing negative regulation of the NLRP3 inflammasome activation could attenuate colitis in an animal model.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DSS-induced colitis model in C57BL/6 mice (6-9 weeks old)
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; once daily; 9 days while 2.5% DSS treatment began on day 1 and ended on day 7
Result:	Significantly attenuated the weight loss of DSS-induced colitis mice compared to PBS-treated control mice, indicating that decreasing negative regulation of the NLRP3 inflammasome activation could attenuate colitis in an animal model.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (451.98 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.5198 mL	22.5989 mL	45.1977 mL
5 mM	0.9040 mL	4.5198 mL	9.0395 mL
10 mM	0.4520 mL	2.2599 mL	4.5198 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (11.30 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (11.30 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (11.30 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (11.30 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (11.30 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (11.30 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。